Mesenchymal stromal cells for treatment of steroid-refractory GvHD: A review of the literature and two pediatric cases

International Archives of Medicine

Volumn 4, Issue 1, 2011, Pages

  Wernicke, Caroline M ^a   Grunewald, Thomas G P ^a,b   Hendrik, Juenger ^a   Kuci, Selim ^c   Kuci, Zyrafete ^c   Koehl, Ulrike ^c   Mueller, Ingo ^d   Doering, Michaela ^e   Peters, Christina ^f   Lawitschka, Anita ^f   Kolb, Hans Jochem ^a   Bader, Peter ^c   Burdach, Stefan ^a   Von Luettichau, Irene ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; ETANERCEPT; FLUDARABINE; GLUCOCORTICOID; MELPHALAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PSORALEN; THIOTEPA; TOPOTECAN; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; DIARRHEA; DRUG MEGADOSE; DYSPNEA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LITERATURE; MESENCHYME STROMA CELL; META ANALYSIS; OUTCOME ASSESSMENT; PANCYTOPENIA; PUVA; RESPIRATORY DISTRESS; REVIEW; RHABDOMYOSARCOMA; STEM CELL TRANSPLANTATION; STEROID REFRACTORY GRAFT VERSUS HOST REACTION; STROMA CELL; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TISSUE REPAIR; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 80051577003     PISSN: None     EISSN: 17557682     Source Type: Journal    
DOI: 10.1186/1755-7682-4-27     Document Type: Review

References (85)

1. No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Thiel U, Wawer A, Wolf P, Badoglio M, Santucci A, Klingebiel T, Basu O, Borkhardt A, Laws HJ, Kodera Y, et al. Ann Oncol 2011 22 7 1614 1621 10.1093/annonc/mdq703 21245159
2. Chronic graft-versus-host disease (GVHD) in children. Baird K, Cooke K, Schultz KR, Pediatr Clin North Am 2010 57 1 297 322 10.1016/j.pcl.2009.11.003 20307722
3. Have we made progress in the management of chronic graft-vs-host disease? Lee SJ, Best Pract Res Clin Haematol 2010 23 4 529 535 10.1016/j.beha.2010.09. 016 21130418
4. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, et al. Lancet 2008 371 9624 1579 1586 10.1016/S0140-6736(08)60690-X 18468541 (Pubitemid 351626841)
5. Prevention and treatment of acute GvHD. Messina C, Faraci M, de Fazio V, Dini G, Calo MP, Calore E, Bone Marrow Transplant 2008 41 Suppl 2 65 70 18545247
6. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noel D, Stem Cell Res Ther 2010 1 1 2 10.1186/scrt2 20504283
7. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Shi Y, Hu G, Su J, Li W, Chen Q, Shou P, Xu C, Chen X, Huang Y, Zhu Z, et al. Cell Res 2010 20 5 510 518 10.1038/cr.2010.44 20368733
8. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H, J Immunol 2010 185 1 302 312 10.4049/jimmunol.0902007 20511548
9. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, Ruadkow IA, Exp Hematol 1974 2 2 83 92 4455512
10. Mesenchymal stem cell differentiation and roles in regenerative medicine. Hwang NS, Zhang C, Hwang YS, Varghese S, Wiley Interdiscip Rev Syst Biol Med 2009 1 1 97 106 10.1002/wsbm.26 20835984
11. Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Djouad F, Bouffi C, Ghannam S, Noel D, Jorgensen C, Nat Rev Rheumatol 2009 5 7 392 399 10.1038/nrrheum.2009.104 19568253
12. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F, Cantos C, Jorgensen C, Noel D, Stem Cells 2007 25 8 2025 2032 10.1634/stemcells.2006-0548 17510220 (Pubitemid 47258180)
13. Human mesenchymal stem cells modulate allogeneic immune cell responses. Aggarwal S, Pittenger MF, Blood 2005 105 4 1815 1822 10.1182/blood-2004-04-1559 15494428 (Pubitemid 40223708)
14. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A, Haematologica 2007 92 7 881 888 10.3324/haematol.11240 17606437 (Pubitemid 350144234)
15. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Rasmusson I, Ringden O, Sundberg B, Le Blanc K, Transplantation 2003 76 8 1208 1213 10.1097/01.TP.0000082540.43730.80 14578755 (Pubitemid 37339646)
16. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Tabera S, Perez-Simon JA, Diez-Campelo M, Sanchez-Abarca LI, Blanco B, Lopez A, Benito A, Ocio E, Sanchez-Guijo FM, Canizo C, et al. Haematologica 2008 93 9 1301 1309 10.3324/haematol.12857 18641017
17. Mesenchymal stem cells suppress B-cell terminal differentiation. Asari S, Itakura S, Ferreri K, Liu CP, Kuroda Y, Kandeel F, Mullen Y, Exp Hematol 2009 37 5 604 615 10.1016/j.exphem.2009.01.005 19375651
18. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Shi M, Liu ZW, Wang FS, Clin Exp Immunol 2011 164 1 1 8 10.1111/j.1365-2249.2011.04327.x 21466544
19. Interactions between human mesenchymal stem cells and natural killer cells. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M, Stem Cells 2006 24 1 74 85 10.1634/stemcells.2004-0359 16099998
20. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F, et al. Stem Cells 2006 24 2 386 398 10.1634/stemcells.2005-0008 16123384 (Pubitemid 44464808)
21. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y, Cell Stem Cell 2008 2 2 141 150 10.1016/j.stem.2007. 11.014 18371435 (Pubitemid 351181031)
22. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D, Blood 2004 103 12 4619 4621 10.1182/blood-2003-11-3909 15001472 (Pubitemid 38745993)
23. Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase. Maby-El Hajjami H, Ame-Thomas P, Pangault C, Tribut O, DeVos J, Jean R, Bescher N, Monvoisin C, Dulong J, Lamy T, et al. Cancer Res 2009 69 7 3228 3237 10.1158/0008-5472.CAN-08-3000 19276371
24. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, et al. Nat Med 2009 15 1 42 49 10.1038/nm.1905 19098906
25. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L, Blood 2009 113 26 6576 6583 10.1182/blood-2009-02-203943 19398717
26. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N, Blood 2005 105 10 4120 4126 10.1182/blood-2004-02-0586 15692068 (Pubitemid 40656164)
27. Stem cell homing in musculoskeletal injury. Fong EL, Chan CK, Goodman SB, Biomaterials 2011 32 2 395 409 10.1016/j.biomaterials.2010.08.101 20933277
28. Human adult CD34- progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Von Luttichau I, Notohamiprodjo M, Wechselberger A, Peters C, Henger A, Seliger C, Djafarzadeh R, Huss R, Nelson PJ, Stem Cells Dev 2005 14 3 329 336 10.1089/scd.2005.14.329 15969628 (Pubitemid 40885257)
29. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, Laine GA, Cox CS Jr, Stem Cells Dev 2009 18 5 683 692 10.1089/scd.2008.0253 19099374
30. Nonmyeloablative stem cell therapy enhances microcirculation and tissue regeneration in murine inflammatory bowel disease. Khalil PN, Weiler V, Nelson PJ, Khalil MN, Moosmann S, Mutschler WE, Siebeck M, Huss R, Gastroenterology 2007 132 3 944 954 10.1053/j.gastro.2006.12.029 17383423 (Pubitemid 46440862)
31. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, Hua B, Liu B, Ye S, Hu X, et al. Arthritis Rheum 62 8 2467 2475
32. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Tyndall A, Uccelli A, Bone Marrow Transplant 2009 43 11 821 828 10.1038/bmt.2009.63 19308035
33. Mesenchymal stromal cells for graft-versus-host disease: basic aspects and clinical outcomes. Sato K, Ozaki K, Mori M, Muroi K, Ozawa K, J Clin Exp Hematop 2010 50 2 79 89 10.3960/jslrt.50.79 21123965
34. Mesenchymal stromal cells for graft-versus-host disease. Tolar J, Villeneuve P, Keating A, Hum Gene Ther 2011 22 3 257 262 10.1089/hum.2011.1104 21288086
35. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. Wakitani S, Okabe T, Horibe S, Mitsuoka T, Saito M, Koyama T, Nawata M, Tensho K, Kato H, Uematsu K, et al. J Tissue Eng Regen Med 2011 5 2 146 150 10.1002/term.299 20603892
36. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. Kuroda R, Ishida K, Matsumoto T, Akisue T, Fujioka H, Mizuno K, Ohgushi H, Wakitani S, Kurosaka M, Osteoarthritis Cartilage 2007 15 2 226 231 10.1016/j.joca.2006.08. 008 17002893 (Pubitemid 46132105)
37. Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. Wakitani S, Nawata M, Tensho K, Okabe T, Machida H, Ohgushi H, J Tissue Eng Regen Med 2007 1 1 74 79 10.1002/term.8 18038395
38. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Conget P, Rodriguez F, Kramer S, Allers C, Simon V, Palisson F, Gonzalez S, Yubero MJ, Cytotherapy 2010 12 3 429 431 10.3109/14653241003587637 20230217
39. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Woodley DT, Chen M, Riddle MJ, Osborn MJ, Lund T, et al. N Engl J Med 2010 363 7 629 639 10.1056/NEJMoa0910501 20818854
40. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Tolar J, Ishida-Yamamoto A, Riddle M, McElmurry RT, Osborn M, Xia L, Lund T, Slattery C, Uitto J, Christiano AM, et al. Blood 2009 113 5 1167 1174 18955559
41. Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. Hocking AM, Gibran NS, Exp Cell Res 2010 316 14 2213 2219 10.1016/j.yexcr.2010.05.009 20471978
42. Mesenchymal-epithelial interactions in the skin: aiming for site-specific tissue regeneration. Yamaguchi Y, Hearing VJ, Itami S, Yoshikawa K, Katayama I, J Dermatol Sci 2005 40 1 1 9 10.1016/j.jdermsci.2005.04.006 16157476 (Pubitemid 41383892)
43. Mesenchymal stromal cells to treat cardiovascular disease: strategies to improve survival and therapeutic results. Noort WA, Feye D, Van Den Akker F, Stecher D, Chamuleau SA, Sluijter JP, Doevendans PA, Panminerva Med 2010 52 1 27 40 20657531
44. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Psaltis PJ, Zannettino AC, Worthley SG, Gronthos S, Stem Cells 2008 26 9 2201 2210 10.1634/stemcells.2008-0428 18599808
45. The potential use of stem cells in multiple sclerosis: an overview of the preclinical experience. Karussis D, Kassis I, Clin Neurol Neurosurg 2008 110 9 889 896 10.1016/j.clineuro.2008.02.008 18375051
46. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Kassis I, Grigoriadis N, Gowda-Kurkalli B, Mizrachi-Kol R, Ben-Hur T, Slavin S, Abramsky O, Karussis D, Arch Neurol 2008 65 6 753 761 10.1001/archneur.65.6.753 18541795 (Pubitemid 351831453)
47. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, et al. Blood 2005 106 5 1755 1761 10.1182/blood-2005-04-1496 15905186 (Pubitemid 41208591)
48. Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Gordon D, Pavlovska G, Glover CP, Uney JB, Wraith D, Scolding NJ, Neurosci Lett 2008 448 1 71 73 10.1016/j.neulet.2008.10.040 18950680
49. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Zhang J, Li Y, Chen J, Cui Y, Lu M, Elias SB, Mitchell JB, Hammill L, Vanguri P, Chopp M, Exp Neurol 2005 195 1 16 26 10.1016/j.expneurol.2005.03.018 15904921 (Pubitemid 41116810)
50. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, Pistoia V, Martin I, Tyndall A, Rheumatology (Oxford) 2007 46 3 403 408 10.1093/rheumatology/kel267 (Pubitemid 46344649)
51. Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Urban VS, Kiss J, Kovacs J, Gocza E, Vas V, Monostori E, Uher F, Stem Cells 2008 26 1 244 253 10.1634/stemcells.2007-0267 17932424
52. Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study. Arima N, Nakamura F, Fukunaga A, Hirata H, Machida H, Kouno S, Ohgushi H, Cytotherapy 2010 12 2 265 268 10.3109/14653240903390795 19961282
53. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Fang B, Song Y, Liao L, Zhang Y, Zhao RC, Transplant Proc 2007 39 10 3358 3362 10.1016/j.transproceed. 2007.08.103 18089385 (Pubitemid 350251475)
54. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, et al. Biol Blood Marrow Transplant 2009 15 7 804 811 10.1016/j.bbmt.2008.03.012 19539211
55. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, et al. Biol Blood Marrow Transplant 2005 11 5 389 398 10.1016/j.bbmt.2005.02.001 15846293 (Pubitemid 40542932)
56. Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: a report of two cases. Lim JH, Lee MH, Yi HG, Kim CS, Kim JH, Song SU, Int J Hematol 2010 92 1 204 207 10.1007/s12185-010-0606-9 20514533
57. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, et al. Transplantation 2006 81 10 1390 1397 10.1097/01.tp.0000214462.63943.14 16732175 (Pubitemid 43847148)
58. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K, Platzbecker U, Illmer T, Schaich M, Schetelig J, et al. Bone Marrow Transplant 2009 43 3 245 251 10.1038/bmt.2008.316 18820709
59. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, Wu SJ, Luo CW, Guo R, Ling W, et al. Bone Marrow Transplant 2010 45 12 1732 1740 10.1038/bmt.2010.195 20818445
60. [Mesenchymal stem cells for treatment of steroid-resistant chronic graft-versus-host disease]. Zhang LS, Liu QF, Huang K, Zhang Y, Fan ZP, Huang SL, Zhonghua Nei Ke Za Zhi 2009 48 7 542 546 19957792
61. Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Fang B, Song Y, Lin Q, Zhang Y, Cao Y, Zhao RC, Ma Y, Pediatr Transplant 2007 11 7 814 817 10.1111/j.1399-3046.2007.00780.x 17910665 (Pubitemid 47512333)
62. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, Monroy R, Kurtzberg J, Biol Blood Marrow Transplant 2010 17 4 534 541 20457269
63. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, Salvade A, Capelli C, Belotti D, Gaipa G, et al. Biol Blood Marrow Transplant 2010 16 9 1293 1301 10.1016/j.bbmt.2010.03.017 20350611
64. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O, Lancet 2004 363 9419 1439 1441 10.1016/S0140-6736(04)16104-7 15121408 (Pubitemid 38586721)
65. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Muller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F, Dominici M, Greil J, Handgretinger R, Blood Cells Mol Dis 2008 40 1 25 32 10.1016/j.bcmd.2007.06.021 17869550 (Pubitemid 350199635)
66. Prochymal improves response rates in patients with steroid-refractory acute graft-versus-host disease involving the liver and gut: results of a randomized, placebo-controlled, multicentre phase III trial in GvHD. Martin P, Bone Marrow Transplantation 2010 45 1 77 20372162
67. Genzyme backs Osiris, despite Prochymal flop. Allison M, Nat Biotechnol 2009 27 11 966 967 10.1038/nbt1109-966 19898434
68. Impact of graft-versus-host disease on survival. Pasquini MC, Best Pract Res Clin Haematol 2008 21 2 193 204 10.1016/j.beha.2008.02.011 18503986 (Pubitemid 351714759)
69. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Kolb HJ, Blood 2008 112 12 4371 4383 10.1182/blood-2008-03-077974 19029455
70. Childhood rhabdomyosarcoma. Rodeberg D, Paidas C, Semin Pediatr Surg 2006 15 1 57 62 10.1053/j.sempedsurg.2005.11.009 16458847 (Pubitemid 43177163)
71. Muscling in: Uncovering the origins of rhabdomyosarcoma. Hettmer S, Wagers AJ, Nat Med 2010 16 2 171 173 10.1038/nm0210-171 20134473
72. Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children. Kazanowska B, Reich A, Stegmaier S, Bekassy AN, Leuschner I, Chybicka A, Koscielniak E, Fetal Pediatr Pathol 2007 26 1 17 31 10.1080/15513810701394702 17613043 (Pubitemid 47035965)
73. Soft tissue sarcoma in children: prognosis and management. Koscielniak E, Morgan M, Treuner J, Paediatr Drugs 2002 4 1 21 28 11817983 (Pubitemid 34208343)
74. Sclerosing epithelioid fibrosarcoma of the bone: a case report of high resistance to chemotherapy and a survey of the literature. Grunewald TG, von Luettichau I, Weirich G, Wawer A, Behrends U, Prodinger PM, Jundt G, Bielack SS, Gradinger R, Burdach S, Sarcoma 2010 2010 431627 20396630
75. Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases. Burdach S, Thiel U, Schoniger M, Haase R, Wawer A, Nathrath M, Kabisch H, Urban C, Laws HJ, Dirksen U, et al. Bone Marrow Transplant 2010 45 3 483 489 10.1038/bmt.2009.184 19684633
76. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Lang P, Pfeiffer M, Muller I, Schumm M, Ebinger M, Koscielniak E, Feuchtinger T, Foll J, Martin D, Handgretinger R, Klin Padiatr 2006 218 6 321 326 10.1055/s-2006-942256 17080334 (Pubitemid 44862390)
77. Fungal infections in transplant and oncology patients. Person AK, Kontoyiannis DP, Alexander BD, Infect Dis Clin North Am 2010 24 2 439 459 10.1016/j.idc.2010.01.002 20466278
78. Viral infections in transplant recipients. Razonable RR, Eid AJ, Minerva Med 2009 100 6 479 501 20010483
79. Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft-versus-host disease. Greinix HT, Worel N, Knobler R, Biol Blood Marrow Transplant 2010 16 12 1747 1748 author reply 1749 10.1016/j.bbmt.2010.06.012 20601039
80. Acute graft-versus-host disease in children. Jacobsohn DA, Bone Marrow Transplant 2008 41 2 215 221 10.1038/sj.bmt.1705885 17934526 (Pubitemid 351188920)
81. The incidence and risk factors for chronic graft-versus-host-disease. Wojnar J, Giebel S, Holowiecka-Goral A, Krawczyk-Kulis M, Markiewicz M, Wozniczka K, Holowiecki J, Ann Transplant 2006 11 2 14 20 discussion 32-43 17494284
82. Acute graft-versus-host disease. The incidence and risk factors. Wojnar J, Giebel S, Krawczyk-Kulis M, Markiewicz M, Kruzel T, Wylezol I, Czerw T, Seweryn M, Holowiecki J, Ann Transplant 2006 11 1 16 23 17715573
83. The allogeneic graft-versus-cancer effect. Ringden O, Karlsson H, Olsson R, Omazic B, Uhlin M, Br J Haematol 2009 147 5 614 633 10.1111/j.1365-2141.2009. 07886.x 19735262
84. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, Yu Z, Li B, Xu C, Li Y, et al. Leukemia 2008 22 3 593 599 10.1038/sj.leu.2405090 18185520 (Pubitemid 351386730)
85. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, Vanbellinghen JF, Hafraoui K, Lejeune M, Gothot A, et al. Biol Blood Marrow Transplant 2010 16 6 838 847 10.1016/j.bbmt.2010.01.011 20109568